Court rules in favour of Sanofi in FemPatch case:
This article was originally published in Clinica
Executive Summary
The Tribunal of the International Chamber of Commerce has ruled in favour of Sanofi in a case brought by the French company against Cygnus. US company Cygnus breached its contract regarding commercialisation of Cygnus' FemPatch, a transdermal hormone replacement therapy patch. The amount of damages is yet to be decided; Sanofi's initial request was for not less than $10 million, plus royalties on future HRT transdermal systems, a sum towards lost market share and the costs of arbitration.
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.